Beclomethasone Aeronative 250mcg/dose 200doses

Beclomethasone Aeronative - glucocorticosteroid (GCS) anti-asthma action for inhalation use.

Release form and composition

The drug is produced in the form of an aerosol for metered-dose inhalation: a clear, colorless liquid, which is kept under pressure in a cylinder, is sprayed upon exit as an aerosol jet (200 doses each in an aluminum bottle with a spray nozzle for dosing action, 1 container in a cardboard bundle and instructions for use of Beclomethasone - aeronativ).
Composition for 1 dose:
    active substance: beclomethasone dipropionate - 50/100/250 mcg;
    additional components: triethyl citrate, brand A absolute ethyl alcohol, R 134a propellant (1,1,1,2-tetrafluoroethane).

Pharmacodynamics

Beclomethasone dipropionate belongs to prodrugs and has a weak tropism for GCS receptors. Due to the action of esterases, it is biotransformed into the active metabolite of Beclomethasone -17-monopropionate (B-17-MP), which has a pronounced local anti-inflammatory effect. As a result of a decrease in the formation of chemotaxis substance, the active component reduces inflammation (effect on late-type allergy reactions), slows down the development of an immediate type of allergic reaction, which is caused by inhibition of the production of arachidonic acid metabolites and weakening of the release of inflammatory mediators by mast cells, and increases the speed of mucociliary transport.
Beclomethasone provides a decrease in the number of mast cells in the bronchial mucosa, a decrease in epithelial edema, inhibition of bronchial hyperreactivity, and mucus production by the bronchial glands. The active substance reduces the formation of inflammatory exudate, the secretion of lymphokines, marginal accumulation of neutrophils, and also helps to slow down the migration of macrophages, weakening the intensity of the processes of infiltration and granulation. With the use of Beclomethasone Aeronative, the number of active β-adrenergic receptors increases, the patient's reaction to bronchodilators is restored, which makes it possible to reduce the frequency of their use. After inhalation, the agent almost does not show a resorptive effect. Beclomethasone Aeronative is not intended to relieve bronchospasm, its therapeutic effect develops gradually, usually 5-7 days after the start of the course.

Pharmacokinetics

When inhaled, more than 25% of the dose of beclomethasone gets into the respiratory tract, and the rest settles in the oral cavity, pharynx and is swallowed. Before absorption in the lungs, the substance forms an active metabolite B-17-MP as a result of intensive metabolic transformation. Systemic absorption of this metabolite occurs in the lungs (36% of the pulmonary fraction) and the digestive tract (26% of the dose that got here after swallowing). The absolute bioavailability of beclomethasone dipropionate unchanged and B-17-MP is on average 2 and 62% of the inhaled dose. Beclomethasone is characterized by a high absorption rate. The maximum concentration (Cmax) of a substance in plasma is observed 0.3 hours after administration. The metabolite B-17-MP is absorbed more slowly, the period of reaching its Cmax is approximately 1 hour.
An approximate linear relationship was established between an increase in the dose administered as inhalation and a systemic exposure of the active substance. The distribution of beclomethasone dipropionate in the tissues is 20 l, B-17-MP - 424 l, plasma clearance - 150 and 120 l / h, respectively. Up to 87% of the drug binds to plasma proteins. The half-life (T1 / 2) of the active substance and its metabolite is 0.5 and 2.7 hours, respectively.

Indications for use

    bronchial asthma: basic therapy of various forms of the disease in children older than 4 years and adults;
    chronic obstructive pulmonary disease (COPD): maintenance therapy in patients with forced expiratory volume (FEV1) less than 50% of the expected values ​​(after inhalation of the bronchodilator) and with a history of repeated exacerbations in which severe symptoms of the disease persist despite regular treatment bronchodilators.

Contraindications

Absolute:
    children under four years old;
    hypersensitivity to any component of the drug.
Relative (use of Beclomethasone Aeronative is required with caution): systemic infections (viral, bacterial, fungal, parasitic), glaucoma, pulmonary tuberculosis (active / inactive form), osteoporosis, hypothyroidism, liver cirrhosis, pregnancy and lactation.

Instructions for use: method and dosage

Aerosol Beclomethasone Aeronative is indicated exclusively for the inhalation route of administration.
Rules for inhalation:
    Before the first use of the inhaler or in the case when it has not been used for 7 days or more, to check the operation of the cylinder, it is necessary to remove the protective cap from the mouthpiece, shake the inhaler vigorously and press it, releasing one jet of the drug into the air.
    To carry out the inhalation administration of the aerosol, Beclomethasone Aeronative should remove the protective cap from the mouthpiece of the inhaler and shake the balloon vigorously. Then, holding the last bottom up, after a slow full exhalation, tightly grasp the mouthpiece with your lips. Having taken the deepest possible breath, simultaneously quickly press the bottom of the balloon to release 1 inhaled dose. After that, holding your breath for a few seconds, you should remove the mouthpiece from your mouth and slowly exhale; close the mouthpiece of the inhaler with a protective cap.
    If necessary, the second dose is administered in a similar manner, but without shaking the inhaler at the beginning of the procedure.
    In order to avoid the development of candidiasis, after inhalation, rinse the mouth and throat with boiled water, while the water can not be swallowed.
    Once a week, you need to clean the mouthpiece of the inhaler. For this purpose, you need to remove the metal can from the case and rinse the case and cap with warm (but not hot) water, and then dry thoroughly, without using heating devices. You can not dip a metal can into water. After drying, the can is put back into the case and put on the cap.

Bronchial asthma

The daily dose of the drug is administered in several doses. Adults and adolescents 12 years of age and older for regular therapy of Beclomethasone Aeronative should be used regularly, even in the absence of symptoms of the disease. The dose of the drug is set individually, taking into account the severity of bronchial asthma and the clinical effect.
Recommended initial daily doses of Beclomethasone Aeronative depending on the severity of the disease:
    mild course - 200-600 mcg;
    moderate course - 600–1000 mcg;
    severe course - 1000–2000 mcg.
Children from 4 to 12 years of age are prescribed beclomethasone aeronativ in a daily dose of up to 400 mcg.
Taking into account the individual response of the patient to the treatment, the dose can be increased until a clinical effect occurs or reduced to the least effective. If it is necessary to switch to the use of the drug in a high dose for many patients receiving systemic corticosteroids, it becomes possible to reduce the dose of the latter or cancel their intake.

Chronic Obstructive Pulmonary Disease (COPD)

With maintenance therapy for COPD, the recommended maximum daily dose of Beclomethasone Aeronative is 2000 mcg.
If the next inhalation was accidentally missed, the next dose is used at the usual time according to the treatment regimen.
The introduction of funds can be done using special dispensers (spacers) that improve the distribution of the active substance in the lungs and reduce the risk of side effects.

Side effects

    respiratory system: often - cough; rarely - pharyngeal irritation, paradoxical bronchospasm, dysphonia that occurs after completion of therapy or a decrease in the dose of the drug;
    metabolism: rarely - hypercorticism; extremely rarely - signs of systemic corticosteroids effects, including Cushing's syndrome and adrenal hypofunction;
    musculoskeletal system: a decrease in the mineral density of bone tissue;
    immune system: rarely - rash, urticaria, pruritus, angioedema, hypersensitivity reactions;
    others: often - candidiasis of the mucous membrane of the oral cavity and larynx.
When using Beclomethasone Aeronative in high doses for a long time, the systemic effect of inhaled GCS can be observed.

Overdose

Against the background of an acute overdose of the drug, a temporary decrease in the function of the adrenal cortex is possible. With this complication, the appointment of emergency treatment is not required, since the function of the cortex of these endocrine glands is restored within a few days, as evidenced by the plasma cortisol content. In case of chronic overdose, persistent suppression of the activity of the adrenal cortex may occur, in which the functional reserves of the cortical layer should be monitored.
Drug overdose therapy can be continued in doses that are sufficient to maintain a therapeutic effect. In order to prevent overdose, do not use Beclomethasone Aeronative in doses exceeding the recommended ones. It is required to conduct a regular assessment of the effectiveness of treatment and reduce the administered dose to a minimum level that provides adequate control of the symptoms of the disease.

special instructions

Before conducting therapy with Beclomethasone Aeronative, the patient should be instructed on the rules for its use, ensuring the maximum flow of funds to the desired areas of the lungs. For the treatment of oral candidiasis against the background of a long course of treatment, concomitant use of local antifungal agents is allowed.
If Beclomethasone Aeronative begins to be used by patients taking oral glucocorticosteroids, the doses of the latter are not corrected at the initial stage of joint use, while the condition of the patients should be relatively stable. Then, on average, after 1-2 weeks, the daily dose of oral GCS is gradually reduced. Treatment with inhaled corticosteroids, provided that they are regularly used, in most cases makes it possible to cancel oral corticosteroids (patients who need to take no more than 1,500 μg of prednisolone can be fully transferred to inhalation therapy). In this case, in the first months after switching to inhalation, the patient needs to carefully monitor the condition and monitor the indicators of adrenal cortex function until his pituitary-adrenal system is restored in sufficient volume and can provide an adequate response to stressful situations (surgical intervention , injury, infection).
When patients switch from taking systemic corticosteroids to inhalation treatment, it is possible to develop allergic reactions, such as allergic rhinitis, eczema, which were previously suppressed by systemic drugs.
With reduced function of the adrenal cortex in patients who switched to the use of inhaled drugs, there must always be a reserve of corticosteroids. Also, patients of this risk group should always have a warning card with them, in which they need to indicate the need for them to appoint additional systemic GCS in stressful situations (after eliminating this situation, the dose of these drugs can be reduced).
A sharp and progressive worsening of asthma symptoms is a potentially dangerous condition that often threatens the lives of patients and requires an increase in the dose of corticosteroids. An indirect indicator of the ineffectiveness of therapy is an increase in the frequency of use, when compared with the previous period, of short-acting β2-adrenostimulants. With a significant exacerbation of the course of bronchial asthma or an insufficient effect of the treatment, the dose of the drug should be increased, and if necessary, a systemic corticosteroids and / or antibiotic should be prescribed against the background of infection.
Beclomethasone Aeronative is indicated for regular daily use and is not recommended for stopping attacks, for this purpose β2-adrenostimulants of short action, such as salbutamol, are used.
If there is a development of paradoxical bronchospasm, it is immediately necessary to stop using Beclomethasone Aeronative and conduct an examination. After which, on the recommendation of the attending physician, it is possible to switch to taking other medicines.
In most patients, the use of the drug in a daily dose of 1500 μg does not lead to a significant suppression of adrenal function.
Due to the threat of an exacerbation of the disease, abrupt withdrawal of Beclomethasone Aeronative is required to be avoided, the dose must be reduced gradually under the supervision of a doctor.
You should be careful not to get the solution in your eyes, to prevent damage to the skin of the nose and eyelids after inhalation, it is recommended to wash your face.
Aluminum can, even if it is empty, it is forbidden to disassemble, puncture or throw into the fire.
Since the effect of Beclomethasone Aeronative may weaken at low temperatures, before carrying out inhalation, the cooled can should be removed from the plastic case and warm in the palms for several minutes.

Influence on the ability to drive vehicles and complex mechanisms

Beclomethasone dipropionate does not adversely affect the ability to perform potentially dangerous types of work, including the management of complex moving machinery and vehicles.

Pregnancy and lactation

During pregnancy and breastfeeding, beclomethasone aeronativ can be prescribed only if the expected benefit for the woman significantly exceeds any possible threat to the fetus or child.

Use in childhood

Children under 4 years of age are contraindicated to use Beclomethasone Aeronative.

With impaired renal function

In patients with functional impairment of renal function, a dose reduction is not necessary.

With impaired liver function

With diagnosed cirrhosis, Beclomethasone Aeronative should be used with extreme caution. For patients with functional impairment of hepatic function, dose adjustment is not required.

Drug interaction

There is no confirmed information on the drug interaction of beclomethasone dipropionate with other substances / agents.

Terms and conditions of storage

Keep out of the reach of children, protected from light, away from heaters, at a temperature not exceeding 25 ° C. Keep away from freezing.
Shelf life is 2 years.

Reviews

According to a few reviews, Beclomethasone Aeronative is an effective tool used for the basic treatment of bronchial asthma and maintenance treatment of COPD. Patients note that the drug effectively helps fight asthma, is not addictive and is well tolerated. They also indicate that the use of inhaled GCS is safer than taking systemic drugs of this class. According to many patients, this drug is a worthy replacement for expensive foreign analogues.
The lack of inhalation aerosol Beclomethasone Aeronative consider the appearance of side effects, mainly in the form of candidiasis of the laryngeal mucosa and oral cavity.

Terms of sell

You don't need a prescription to buy Beclomethasone Aeronative.